AstraZeneca to introduce COPD inhaler Breztri Aerosphere in India

19 Nov 2024 , 09:50 AM

AstraZeneca Pharma India Ltd said that the company has secured permission from the Drugs Controller General of India (DCGI) for the import and market of Breztri Aerosphere, an inhalation preparation containing budesonide (160mcg), glycopyrronium (7.2mcg), and formoterol fumarate dihydrate (5mcg).

This combination drug is used to treat chronic obstructive pulmonary disease (COPD) in adults, relieving symptoms and preventing exacerbations.

Regarding this, AstraZeneca Pharma India Limited has announced that Breztri Aerosphere will be launched in India in January 2025.

“We refer to our earlier communication dated December 2, 2023, intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Breztri Aerosphere,” said the company in an exchange filing.

The company’s sales for the quarter was ₹408 Crore, up 31.16% year on year. However, profit declined by 26.62% to ₹38.43 Crore. In compared to the previous quarter, Astrazeneca Pharma India saw 5.28% sales growth and a spectacular profit gain of 425.95%.

Operating income improved significantly, growing by 284.62% quarter on quarter, despite a 34.06% reduction year-on-year. EPS for the quarter was ₹15.37, down 5.48% from the previous year.

For feedback and suggestions, write to us at [e-mail]